More and more imaging researchers are starting to examine the potential of using fibroblast activation protein inhibitors (FAPI) to manage patients with suspected cardiovascular disease.
Is portable MRI suitable for finding abnormalities in the brains of patients receiving new amyloid-targeting therapy for Alzheimer’s disease? Clinical researchers are about to find out.
Alexander Fanaroff, MD, said the late-breaking BE ACTIVE clinical trial presented at ACC.24 offers a blueprint for how to get patients to be more physically active.